Anti-Cytokine Therapy for Hemodialysis InflammatION (ACTION): A Phase II Multi-center Study to Evaluate the Safety and Tolerability of Anakinra, an IL-1 Receptor Antagonist, for Patients Treated With Maintenance Hemodialysis
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
Price : $35 *
At a glance
- Drugs Anakinra (Primary)
- Indications Renal failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACTION
- 05 Feb 2019 Planned End Date changed from 1 May 2021 to 1 Jun 2021.
- 05 Feb 2019 Planned primary completion date changed from 1 Apr 2020 to 1 Jun 2020.
- 04 Jan 2018 Status changed from not yet recruiting to recruiting.